Daily pill which doubles survival for UK’s biggest cancer killler to be made routinely available on the NHS

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS.

Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from returning after surgery when taken with chemotherapy.

It has been recommended by the National Institute for Health and Care Excellence (NICE) as an additional treatment for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC).

The EGFR protein controls cell growth, and its mutation is common in NSCLC, causing abnormal growth.

NICE says osimertinib targets EGFR-mutated cells to help prevent cancer from returning after surgery.

Osimertinib, first available through the Cancer Drugs Fund in January 2022, will now be routinely offered on the NHS.

It is estimated that about 600 people in England will benefit from the recommendation.

Helen Knight, director of medicines evaluation at Nice, said: "I am pleased we have been able to recommend that this targeted treatment for a specific gene mutation of lung cancer will be routinely available on the NHS.

"Previously the only treatment for people with this gene mutation of lung cancer where the tumour has been surgically removed was chemotherapy so I know patients will welcome this additional option."

Trials found the median disease-free survival time for patients on osimertinib was 65.8 months compared with 28.1 months for patients taking a placebo.

Some 88 per cent of people on osimertinib also lived for five years compared to 78 per cent of people on the placebo.

Helen added: "At Nice, we are determined to constantly learn from data and implementation and the information gathered during this drug's time in the CDF and further clinical studies mean we can make this positive recommendation."

Lung cancer causes around 34,800 deaths annually in the UK, making up one in five cancer-related deaths.

That's roughly 95 deaths per day.

In the past 10 years, NICE has made 48 positive treatment recommendations for the disease, six times more than in the previous decade.

A patient’s story

Jules Fielder has been taking osimertinib since 2021.

She was diagnosed with stage four lung cancer in 2021 at the age of 37, despite not smoking or having the classic symptoms of the disease, such as a persistent cough.

"Lung cancer has no labels; it can happen to anybody at any age," Ms Fielder said.

"When I had my first scan after three months of being on osimertinib, the cancer had shrunk by 90 per cent in my lungs.

"And I have stayed stable since that day. And because they are tablets, we don't have to go to hospitals and be strapped to machines."

Dr Jesme Fox, medical director of , added: "Another misconception is that if you get lung cancer, there is no hope. That is not true at all.

"If we pick up lung cancer early, then surgery and radiotherapy are potentially curative. And we have seen many advances in the last 10 to 15 years, there are a lot more treatment options now than there used to be."

Professor Peter Johnson, NHS England national clinical director for cancer, said: "It's great news this daily, life-extending pill is now routinely available as another treatment option for all patients in England with this type of lung cancer - secured at a cost-effective price for taxpayers.

"This drug offers the chance of precious additional years of life for hundreds of people following an operation for lung cancer with a specific gene mutation - and is just the latest example of cutting-edge, targeted cancer treatments to which the NHS has secured routine access too for patients."